- Home
- PBYI
as 05-20-2024 10:33am EST
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | LOS ANGELES |
| Market Cap: | 238.3M | IPO Year: | N/A |
| Target Price: | $7.00 | AVG Volume (30 days): | 516.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.32 | EPS Growth: | 220.00 |
| 52 Week Low/High: | $2.13 - $7.73 | Next Earning Date: | 05-02-2024 |
| Revenue: | $226,628,000 | Revenue Growth: | -3.59% |
| Revenue Growth (this year): | -5.1% | Revenue Growth (next year): | -1.01% |
Share on Social Networks:
Stock Insider Trading Activity of Puma Biotechnology Inc (PBYI)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| NOUGUES MAXIMO F | PBYI | Chief Financial Officer | Jan 3 '24 | Sell | $4.49 | 15,682 | $70,347.88 | 128,666 | SEC Form 4 |
| Wong Alvin F | PBYI | Chief Scientific Officer | Jan 3 '24 | Sell | $4.49 | 7,733 | $34,689.46 | 98,214 | SEC Form 4 |
| HUNT DOUGLAS M | PBYI | See Remarks | Jan 3 '24 | Sell | $4.49 | 8,358 | $37,493.15 | 103,319 | SEC Form 4 |
| Wong Alvin F | PBYI | Chief Scientific Officer | Dec 4 '23 | Sell | $3.76 | 280 | $1,053.02 | 97,934 | SEC Form 4 |
| MILLER MICHAEL PATRICK | PBYI | Director | Nov 7 '23 | Sell | $2.83 | 25,000 | $70,802.50 | 43,358 | SEC Form 4 |
Latest Puma Biotechnology Inc News
PBYI Breaking Stock News: Dive into PBYI Ticker-Specific Updates for Smart Investing
Simply Wall St.
15 days ago
Analysts Have Lowered Expectations For Puma Biotechnology, Inc. (NASDAQ:PBYI) After Its Latest Results
Simply Wall St.
16 days ago
Puma Biotechnology First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Insider Monkey
17 days ago
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2024 Earnings Call Transcript
Zacks
17 days ago
Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat
GuruFocus.com
17 days ago
Puma Biotechnology Inc (PBYI) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ...
GuruFocus.com
18 days ago
Puma Biotechnology Inc (PBYI) Reports Q1 Financial Results, Misses Analyst Revenue and EPS Forecasts
Associated Press Finance
18 days ago
Puma Biotech: Q1 Earnings Snapshot
Business Wire
18 days ago